Evidence map›Paper›PMID 33544703›Full record

ArticlePloS one2021

Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment.

Amir H Meghdadi, Marija Stevanović Karić, Marissa McConnell, Greg Rupp, Christian Richard, Joanne Hamilton, David Salat, Chris Berka

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 5 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 5 syntheses or guidelines pooled it, 222 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Amir H MeghdadiAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.ORCID 0000-0001-7863-6488
Marija Stevanović KarićAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
Marissa McConnellAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
Greg RuppAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
Christian RichardAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
Joanne HamiltonUniversity of California, San Diego, San Diego, CA, United States of America.
David SalatMassachusetts General Hospital, Boston, MA, United States of America.
Chris BerkaAdvanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
Advanced Brain Monitoring (United States) · USHarvard University · USUniversity of California San Diego · US

Funding

Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)R44AG050326 · NIA · ADVANCED BRAIN MONITORING, INC. · PI BERKA, CHRIS · 2016 to 2024
$4.4M
Characterizing Alzheimer's Disease with INSPECDS: Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia SubtypesR44AG054256 · NIA · ADVANCED BRAIN MONITORING, INC. · PI BERKA, CHRIS · 2017 to 2018
$1.1M
Interactive Companion Robot for Preventing Neuro-Cognitive Decline in Alzheimer's and Other DementiasR43AG061994 · NIA · ADVANCED BRAIN MONITORING, INC. · PI BERKA, CHRIS · 2018 to 2018
$411k
NIA NIH HHS R43 AG061994NIA NIH HHS R44 AG050326NIA NIH HHS R44 AG054256
6 · The paper itself

Abstract

In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18-40 (n = 129), 40-60 (n = 62) and 60-90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands' power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.

Indexed as

AdolescentAdultAgedAged, 80 and overAlzheimer DiseaseBiomarkersBrainCognitive DysfunctionDisease ProgressionElectroencephalographyFemaleHumansMaleMiddle AgedNeuropsychological TestsYoung AdultBiomarkers

Identifiers

PMID33544703
PMCPMC7864432
OpenAlexW3127942813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.